155 related articles for article (PubMed ID: 37943350)
1. Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective study.
Greimel A; Habler K; Gräfe C; Maciuga N; Brozat CI; Vogeser M; Zoller M; Happich FL; Liebchen U; Frank S; Paal M; Scharf C
Ann Intensive Care; 2023 Nov; 13(1):110. PubMed ID: 37943350
[TBL] [Abstract][Full Text] [Related]
2. Myoglobin adsorption and saturation kinetics of the cytokine adsorber Cytosorb® in patients with severe rhabdomyolysis: a prospective trial.
Graf H; Gräfe C; Bruegel M; Zoller M; Maciuga N; Frank S; Weidhase L; Paal M; Scharf C
Ann Intensive Care; 2024 Jun; 14(1):96. PubMed ID: 38907120
[TBL] [Abstract][Full Text] [Related]
3. Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study.
Scharf C; Liebchen U; Paal M; Becker-Pennrich A; Irlbeck M; Zoller M; Schroeder I
Sci Rep; 2021 May; 11(1):10190. PubMed ID: 33986443
[TBL] [Abstract][Full Text] [Related]
4. Correlation between Bilirubin Elimination with the Cytokine Adsorber CytoSorb® and Mortality in Critically Ill Patients with Hyperbilirubinemia.
Gräfe C; Paal M; Winkels M; Irlbeck M; Liebchen U; Scharf C
Blood Purif; 2023; 52(11-12):849-856. PubMed ID: 37820591
[TBL] [Abstract][Full Text] [Related]
5. Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis.
Luo Y; Decato BE; Charles ED; Shevell DE; McNaney C; Shipkova P; Apfel A; Tirucherai GS; Sanyal AJ
JHEP Rep; 2022 Jan; 4(1):100392. PubMed ID: 34977519
[TBL] [Abstract][Full Text] [Related]
6. Predictive Value of Cellular Accumulation of Hydrophobic Bile Acids As a Marker of Cholestatic Drug Potential.
Burban A; Sharanek A; Humbert L; Eguether T; Guguen-Guillouzo C; Rainteau D; Guillouzo A
Toxicol Sci; 2019 Apr; 168(2):474-485. PubMed ID: 30629237
[TBL] [Abstract][Full Text] [Related]
7. Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis.
Scharf C; Liebchen U; Paal M; Irlbeck M; Zoller M; Schroeder I
Crit Care; 2021 Jan; 25(1):41. PubMed ID: 33509234
[TBL] [Abstract][Full Text] [Related]
8. Extracorporeal liver support techniques: a comparison.
Riva I; Marino A; Valetti TM; Marchesi G; Fabretti F
J Artif Organs; 2023 Jun; ():. PubMed ID: 37335451
[TBL] [Abstract][Full Text] [Related]
9. Cholestatic Alterations in the Critically Ill: Some New Light on an Old Problem.
Jenniskens M; Langouche L; Van den Berghe G
Chest; 2018 Mar; 153(3):733-743. PubMed ID: 28847548
[TBL] [Abstract][Full Text] [Related]
10. Impact of Cytokine Adsorption Treatment in Liver Failure.
Acar U; Gökkaya Z; Akbulut A; Ferah O; Yenidünya Ö; Açık ME; Tokat Y; Yentür E
Transplant Proc; 2019 Sep; 51(7):2420-2424. PubMed ID: 31405742
[TBL] [Abstract][Full Text] [Related]
11. Bile acid indices as biomarkers for liver diseases II: The bile acid score survival prognostic model.
Alamoudi JA; Li W; Gautam N; Olivera M; Meza J; Mukherjee S; Alnouti Y
World J Hepatol; 2021 May; 13(5):543-556. PubMed ID: 34131469
[TBL] [Abstract][Full Text] [Related]
12. Role of bile acids in the diagnosis and progression of liver cirrhosis: A prospective observational study.
Liu N; Feng J; Lv Y; Liu Q; Deng J; Xia Y; Guo C; Zhou Y
Exp Ther Med; 2019 Nov; 18(5):4058-4066. PubMed ID: 31611941
[TBL] [Abstract][Full Text] [Related]
13. Astragalus saponins protect against extrahepatic and intrahepatic cholestatic liver fibrosis models by activation of farnesoid X receptor.
Zhang L; Shi J; Shen Q; Fu Y; Qi S; Wu J; Chen J; Zhang H; Mu Y; Chen G; Liu P; Liu W
J Ethnopharmacol; 2024 Jan; 318(Pt A):116833. PubMed ID: 37400008
[TBL] [Abstract][Full Text] [Related]
14. Hemoadsorption in isolated conjugated hyperbilirubinemia after extracorporeal membrane oxygenation support. Cholestasis of sepsis: A case report and review of the literature on differential causes of jaundice in ICU patient.
Piwowarczyk P; Kutnik P; Potręć-Studzińska B; Sysiak-Sławecka J; Rypulak E; Borys M; Czczuwar M
Int J Artif Organs; 2019 May; 42(5):263-268. PubMed ID: 30919732
[TBL] [Abstract][Full Text] [Related]
15. Cytokine adsorption in patients with acute-on-chronic liver failure (CYTOHEP)-a single center, open-label, three-arm, randomized, controlled intervention trial.
Sekandarzad A; Weber E; Prager EP; Graf E; Bettinger D; Wengenmayer T; Supady A
Trials; 2022 Mar; 23(1):222. PubMed ID: 35303938
[TBL] [Abstract][Full Text] [Related]
16. Metabolic characteristics of plasma bile acids in patients with intrahepatic cholestasis of pregnancy-mass spectrometric study.
Zheng Q; Shen L; Zhao D; Zhang H; Liang Y; Zhu Y; Khan NU; Liu X; Zhang J; Lin J; Tang X
Metabolomics; 2021 Sep; 17(10):93. PubMed ID: 34595616
[TBL] [Abstract][Full Text] [Related]
17. Cholestatic liver (dys)function during sepsis and other critical illnesses.
Jenniskens M; Langouche L; Vanwijngaerden YM; Mesotten D; Van den Berghe G
Intensive Care Med; 2016 Jan; 42(1):16-27. PubMed ID: 26392257
[TBL] [Abstract][Full Text] [Related]
18. Does the cytokine adsorber CytoSorb
Scharf C; Weinelt F; Schroeder I; Paal M; Weigand M; Zoller M; Irlbeck M; Kloft C; Briegel J; Liebchen U
Ann Intensive Care; 2022 May; 12(1):44. PubMed ID: 35599248
[TBL] [Abstract][Full Text] [Related]
19. Bile acids decrease intracellular bilirubin levels in the cholestatic liver: implications for bile acid-mediated oxidative stress.
Muchova L; Vanova K; Zelenka J; Lenicek M; Petr T; Vejrazka M; Sticova E; Vreman HJ; Wong RJ; Vitek L
J Cell Mol Med; 2011 May; 15(5):1156-65. PubMed ID: 20518850
[TBL] [Abstract][Full Text] [Related]
20. Metabolic preconditioning protects BSEP/ABCB11
Fuchs CD; Paumgartner G; Wahlström A; Schwabl P; Reiberger T; Leditznig N; Stojakovic T; Rohr-Udilova N; Chiba P; Marschall HU; Trauner M
J Hepatol; 2017 Jan; 66(1):95-101. PubMed ID: 27593105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
